These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28757060)

  • 21. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
    Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
    Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Schäfer W; Reinders T; Schink T
    Vaccine; 2022 Mar; 40(14):2168-2172. PubMed ID: 35232594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
    Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
    AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital.
    Kanamori H; Tokuda K; Ikeda S; Endo S; Ishizawa C; Hirai Y; Takahashi M; Aoyagi T; Hatta M; Gu Y; Yano H; Weber DJ; Kaku M
    Tohoku J Exp Med; 2014 Oct; 234(2):111-6. PubMed ID: 25224029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
    Buxbaum S; Doerr HW; Allwinn R
    Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.
    Ramet J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S49-55. PubMed ID: 18162247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
    Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
    Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
    Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study.
    Ami N; Eyal N; Asaf B; Chen A; Adi B; Drorit A; Neta P; Hajar D; Stav R; Eli S
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34101817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
    Santos EMD; Noronha TG; Alves IS; Cruz RLS; Ferroco CLV; Brum RC; Oliveira PMN; Siqueira MM; Lima MC; Ramos FLP; Bragagnolo CM; Camacho LAB; Maia MLS
    Mem Inst Oswaldo Cruz; 2019 Mar; 114():e180517. PubMed ID: 30843921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.
    Waaijenborg S; Hahné SJ; Mollema L; Smits GP; Berbers GA; van der Klis FR; de Melker HE; Wallinga J
    J Infect Dis; 2013 Jul; 208(1):10-6. PubMed ID: 23661802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations.
    Heijstek MW; Ott de Bruin LM; Borrow R; van der Klis F; Koné-Paut I; Fasth A; Minden K; Ravelli A; Abinun M; Pileggi G; Borte M; Bijl M; Wulffraat NM
    Autoimmun Rev; 2011 Dec; 11(2):112-22. PubMed ID: 21896342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants.
    Malshe N; Palkar S; Kulkarni R; Lalwani S; Mishra AC; Arankalle V
    Vaccine; 2019 Mar; 37(11):1443-1448. PubMed ID: 30765170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccines for measles, mumps, rubella, varicella, and herpes zoster: immunization guidelines for adults.
    Hendriksz T; Malouf P; Foy JE;
    J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S10-2. PubMed ID: 22086887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.